Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 With Cisplatin and Radiotherapy in High Risk Locally Advanced Head and Neck Squamous Cell Cancer
NCT02113878Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of buparlisib in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Cisplatin at 66 days and Maximum Tolerated Dose of BKM120 at 66 days. Started Sep 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02113878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113878.